S&P 500   4,179.83
DOW   32,908.27
QQQ   347.99
Stock market today: Global shares mostly rise after House approves debt ceiling deal
Save $200 on MarketBeat All Access (Ad)
Alibaba Unveils Its Spin-Off Plans
The Most Upgraded Stocks From The Q1 Earnings Season
Save $200 on MarketBeat All Access (Ad)
Oman launches $5B investment fund as part of efforts to diversify oil-dependant economy
Can the Dow's 2023 Runaway Winners Keep Running?
Your Ultimate Investment Research Platform (Ad)
KLA Shares Soars As Chip Equipment Makers Surge 21% In May
Can These Two Crypto Stocks Stage a Comeback?
S&P 500   4,179.83
DOW   32,908.27
QQQ   347.99
Stock market today: Global shares mostly rise after House approves debt ceiling deal
Save $200 on MarketBeat All Access (Ad)
Alibaba Unveils Its Spin-Off Plans
The Most Upgraded Stocks From The Q1 Earnings Season
Save $200 on MarketBeat All Access (Ad)
Oman launches $5B investment fund as part of efforts to diversify oil-dependant economy
Can the Dow's 2023 Runaway Winners Keep Running?
Your Ultimate Investment Research Platform (Ad)
KLA Shares Soars As Chip Equipment Makers Surge 21% In May
Can These Two Crypto Stocks Stage a Comeback?
S&P 500   4,179.83
DOW   32,908.27
QQQ   347.99
Stock market today: Global shares mostly rise after House approves debt ceiling deal
Save $200 on MarketBeat All Access (Ad)
Alibaba Unveils Its Spin-Off Plans
The Most Upgraded Stocks From The Q1 Earnings Season
Save $200 on MarketBeat All Access (Ad)
Oman launches $5B investment fund as part of efforts to diversify oil-dependant economy
Can the Dow's 2023 Runaway Winners Keep Running?
Your Ultimate Investment Research Platform (Ad)
KLA Shares Soars As Chip Equipment Makers Surge 21% In May
Can These Two Crypto Stocks Stage a Comeback?
S&P 500   4,179.83
DOW   32,908.27
QQQ   347.99
Stock market today: Global shares mostly rise after House approves debt ceiling deal
Save $200 on MarketBeat All Access (Ad)
Alibaba Unveils Its Spin-Off Plans
The Most Upgraded Stocks From The Q1 Earnings Season
Save $200 on MarketBeat All Access (Ad)
Oman launches $5B investment fund as part of efforts to diversify oil-dependant economy
Can the Dow's 2023 Runaway Winners Keep Running?
Your Ultimate Investment Research Platform (Ad)
KLA Shares Soars As Chip Equipment Makers Surge 21% In May
Can These Two Crypto Stocks Stage a Comeback?
NASDAQ:XENT

Intersect ENT (XENT) Stock Forecast, Price & News

Notice: This company has been marked as potentially delisted and may not be actively trading.
Compare
Today's Range
$28.24
$28.24
50-Day Range
$28.24
$28.24
52-Week Range
$15.92
$28.25
Volume
14,512 shs
Average Volume
351,526 shs
Market Capitalization
$954.91 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
N/A

XENT stock logo

About Intersect ENT (NASDAQ:XENT) Stock

Intersect ENT, Inc. operates as an ear, nose, and throat (ENT) medical technology company in the United States. The company offers PROPEL, a steroid releasing implant to open the surgically enlarged sinus; PROPEL Mini, a releasing implant to treat patients undergoing frontal sinus surgery; and PROPEL Contour, a steroid releasing implant for the treatment of frontal and maxillary sinus ostia, or openings, of the dependent sinuses. It also provides SINUVA, a steroid releasing implant for the treatment of patients in the physician office setting; VENSURE Navigable and Stand-alone balloon, a sterile and single-use device, used to access and treat frontal, sphenoid sinus, and maxillary ostia in adults using a trans-nasal approach; and CUBE Navigation System, a virtual guidance platform for high precision ENT and ENT related skull-base surgeries. The company was formerly known as Sinexus, Inc. and changed its name to Intersect ENT, Inc. in November 2009. Intersect ENT, Inc. was incorporated in 2003 and is headquartered in Menlo Park, California.

Receive XENT Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Intersect ENT and its competitors with MarketBeat's FREE daily newsletter.

XENT Stock News Headlines

Highly Profitable Restaurant Brand Expands to Canada
Invest in the Canadian Expansion with Debut: The Exclusive Franchisee with Proven Success.
DexCom (DXCM) Misses Q1 Earnings Estimates
Highly Profitable Restaurant Brand Expands to Canada
Invest in the Canadian Expansion with Debut: The Exclusive Franchisee with Proven Success.
Teleflex (TFX) Q4 Earnings and Revenues Surpass Estimates
Intersect ENT's (XENT) Sell-Off on Track Amid COVID Woes
See More Headlines

Receive XENT Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Intersect ENT and its competitors with MarketBeat's FREE daily newsletter.

XENT Company Calendar

Last Earnings
11/02/2021
Today
6/01/2023
Fiscal Year End
12/31/2023

Industry, Sector and Symbol

Industry
Surgical & Medical Instruments
Sub-Industry
N/A
Sector
Medical
Current Symbol
NASDAQ:XENT
Employees
433
Year Founded
N/A

Profitability

Net Income
$-159,630,000.00
Net Margins
-161.94%
Pretax Margin
-163.16%

Debt

Sales & Book Value

Annual Sales
$106.75 million
Book Value
($2.06) per share

Miscellaneous

Free Float
33,104,000
Market Cap
$954.91 million
Optionable
Optionable
Beta
1.45

Key Executives

  • Mr. Thomas A. West (Age 58)
    Pres, CEO & Director
    Comp: $908.97k
  • Mr. Richard A. Meier (Age 62)
    Exec. VP & CFO
    Comp: $621.76k
  • Mr. Patrick A. Broderick (Age 63)
    Exec. VP, Gen. Counsel & Corp. Sec.
    Comp: $138.46k
  • Ms. Reyna M. Fernandez
    Chief Human Resource Officer
  • Mr. Drake R. Parker (Age 58)
    Advisor of Strategic Initiatives













XENT Stock - Frequently Asked Questions

How were Intersect ENT's earnings last quarter?

Intersect ENT, Inc. (NASDAQ:XENT) released its quarterly earnings data on Tuesday, November, 2nd. The medical equipment provider reported ($0.48) EPS for the quarter, missing analysts' consensus estimates of ($0.42) by $0.06. The medical equipment provider earned $24.40 million during the quarter, compared to the consensus estimate of $29.63 million. Intersect ENT had a negative net margin of 161.94% and a negative trailing twelve-month return on equity of 709.52%.

What is Thomas West's approval rating as Intersect ENT's CEO?

7 employees have rated Intersect ENT Chief Executive Officer Thomas West on Glassdoor.com. Thomas West has an approval rating of 41% among the company's employees. This puts Thomas West in the bottom 10% of approval ratings compared to other CEOs of publicly-traded companies.

What other stocks do shareholders of Intersect ENT own?
What is Intersect ENT's stock symbol?

Intersect ENT trades on the NASDAQ under the ticker symbol "XENT."

What is Intersect ENT's stock price today?

One share of XENT stock can currently be purchased for approximately $28.24.

How much money does Intersect ENT make?

Intersect ENT (NASDAQ:XENT) has a market capitalization of $954.91 million and generates $106.75 million in revenue each year. The medical equipment provider earns $-159,630,000.00 in net income (profit) each year or ($4.79) on an earnings per share basis.

How many employees does Intersect ENT have?

The company employs 433 workers across the globe.

How can I contact Intersect ENT?

Intersect ENT's mailing address is 1555 ADAMS DRIVE, MENLO PARK CA, 94025. The official website for the company is www.intersectent.com. The medical equipment provider can be reached via phone at (650) 641-2100, via email at ir@intersectent.com, or via fax at 866-736-1251.

This page (NASDAQ:XENT) was last updated on 6/1/2023 by MarketBeat.com Staff

My Account -